Monthly Archives: February 2016

BioCryst Plummets After Hereditary Angioedema Drug Disappoints In

Shares of BioCryst Pharmaceuticals (BCRX) are plunging in morning trading after the biotechnology company reported disappointing clinical trial results for its potential hereditary angioedema treatment. What’s new: BioCryst this morning announced results from its OPuS-2 trial evaluating avoralstat in treatment of patients with hereditary angioedema, or HAE. BioCryst said either a 500 mg or 300…

Time For Buy Write ETFs?

The year 2016 saw an appalling start on the bourses as last year’s headwinds spilled over this year with deepening woes. This is especially true as the world’s second largest economy is not showing any sign of reviving anytime soon and the global oil market continues to be overloaded. These two issues have been thwarting…

3 Best-Ranked Legg Mason Mutual Funds

Founded in 1899, Legg Mason is one of the world’s largest asset managers with assets under management of $708 billion. Legg Mason and its affiliates currently manage 112 mutual funds across a wide range of categories, including both equity and fixed-income funds, with over $96.1 billion (excluding money market assets) invested in them. It uses…